Traditional Chinese medicine composition for treating hepatocellular carcinoma and application thereof

Abstract

The invention relates to the technical field of traditional Chinese medicine preparations, and discloses a traditional Chinese medicine composition for treating hepatocellular carcinoma and application thereof, and the traditional Chinese medicine composition comprises the following components in parts by mass: 8-12 parts of ginseng, 13-17 parts of astragalus membranaceus, 8-12 parts of angelica sinensis, 8-12 parts of rhizoma polygonati, 8-12 parts of curcuma zedoary, 18-22 parts of oldenlandia diffusa, 8-12 parts of edible tulip, 3-6 parts of liquorice, 10-15 parts of sculellaria barbata and 5-10 parts of ganoderma lucidum spore powder. In the composition, the ginseng, the astragalus membranaceus and other medicines can enhance the immunity of the organism and protect hepatocytes, the curcuma zedoary, the oldenlandia diffusa and other medicines can directly inhibit tumor growth, and the curcuma zedoary and the oldenlandia diffusa and other medicines cooperate with each other, so that the composition not only improves the physique of a patient, but also plays an anti-tumor role, and accords with the pathogenesis characteristics of deficiency of vital qi and accumulation of pathogenic toxin of liver cancer.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine preparations, and in particular to a traditional Chinese medicine composition for treating hepatocellular carcinoma and application thereof. Background Art

[0002] Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and poses a serious threat to human health. Globally, the morbidity and mortality rates of liver cancer remain high. In my country, the prevention and treatment of liver cancer is particularly challenging due to factors such as the high prevalence of hepatitis B virus infection.

[0003] Currently, treatment options for liver cancer include surgical resection, liver transplantation, local ablation, interventional therapy, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. However, these treatments have numerous limitations. Surgical resection is suitable for patients with early-stage liver cancer, but many patients are already in the advanced stage at the time of diagnosis, making surgery elusive. While liver transplantation is an effective treatment, issues such as donor shortages and postoperative immune rejection limit its widespread use. Interventional therapies such as transcatheter arterial chemoembolization (TACE) can shrink tumors, but are often accompanied by adverse reactions such as nausea, vomiting, fever, and liver damage, and are prone to recurrence. Chemotherapeutic drugs have poor selectivity for liver cancer cells, damaging normal cells while killing cancer cells, resulting in severe toxic side effects that are often difficult for patients to tolerate. Radiotherapy also carries complications such as radiation damage. While targeted therapy and immunotherapy offer new hope for liver cancer treatment, they are ineffective in some patients and pose challenges such as drug resistance and high costs.

[0004] Traditional Chinese Medicine (TCM) offers unique advantages in the treatment of liver cancer. TCM believes that liver cancer is often caused by a deficiency of vital energy, the invasion of pathogenic toxins, leading to organ dysfunction, qi stagnation, blood stasis, and the accumulation of phlegm and toxins. TCM treatments for liver cancer focus on holistic conditioning, combining both attacking and nourishing the body. These methods can enhance the patient's immune system, alleviate clinical symptoms, improve quality of life, and prolong survival, with minimal toxic side effects. However, there is currently a lack of clinically targeted, effective, and stable TCM compositions for the treatment of hepatocellular carcinoma.

[0005] Therefore, developing a safe and effective Chinese medicine composition for treating hepatocellular carcinoma has important practical significance. Summary of the Invention

[0006] In view of this, the present invention proposes a traditional Chinese medicine composition for treating hepatocellular carcinoma and its application, aiming to solve at least one of the above-mentioned background technical problems.

[0007] The present invention provides a traditional Chinese medicine composition for treating hepatocellular carcinoma, comprising the following components in parts by weight:

[0008] 8-12 parts of ginseng, 13-17 parts of astragalus, 8-12 parts of angelica, 8-12 parts of polygonatum, 8-12 parts of zedoaria, 18-22 parts of oldenlandia diffusa, 8-12 parts of trillium, 3-6 parts of liquorice, 10-15 parts of scutellaria barbata and 5-10 parts of ganoderma lucidum spore powder.

[0009] Preferably, the traditional Chinese medicine composition further comprises: 10 to 15 portions of Artemisia capillaris.

[0010] Preferably, the traditional Chinese medicine composition further comprises: 10-15 parts of Poria cocos and 5-8 parts of Alisma orientalis.

[0011] The present invention also provides a method for preparing the traditional Chinese medicine composition for treating hepatocellular carcinoma described in the above technical solution, comprising the following steps:

[0012] Take each component medicinal material, remove impurities, wash and dry, and then grind to obtain 20-40 mesh medicinal material coarse powder;

[0013] Mixing the crude powder of the medicinal material with water, performing a first soaking, then performing a first stage of decoction, and filtering to obtain a first filtrate and a first filter residue;

[0014] adding water to the first filter residue, performing a second stage of decoction, and filtering to obtain a second filtrate and a second filter residue;

[0015] The first filtrate and the second filtrate are mixed and then concentrated to obtain a dry paste;

[0016] The dry paste is dried to obtain dry paste powder, which is the traditional Chinese medicine composition for treating hepatocellular carcinoma.

[0017] Preferably, the mass ratio of the first soaked Chinese medicinal material coarse powder to water is 1:8-12, and the soaking time is 30-60 minutes.

[0018] Preferably, the first stage of decoction is specifically: heating to boiling, and then continuing to decoct for 1.5 to 2.5 hours.

[0019] Preferably, the mass ratio of the first filter residue to water in the second stage of decoction is 1:6-8, and the second stage of decoction is specifically: heating to boiling and then continuing to decoct for 1.0-1.5 hours.

[0020] Preferably, the concentration is specifically as follows: placing the mixture of the first filtrate and the second filtrate in a vacuum concentrator, and concentrating it to a dry paste with a relative density of 1.10-1.20 at 60-70°C and a vacuum degree of 0.06-0.08MPa, wherein the relative density is measured at a temperature of 60°C.

[0021] Preferably, the drying method is spray drying or vacuum freeze drying; the dry paste powder obtained may be made into decoction, tablets, capsules, granules or oral liquid.

[0022] The present invention also provides the use of the traditional Chinese medicine composition for treating hepatocellular carcinoma described in the above technical solution in drugs for treating hepatocellular carcinoma.

[0023] Compared with the prior art, the present invention has the following beneficial effects:

[0024] (1) In the composition of the present invention, ginseng, astragalus and other drugs can enhance the body's immunity and protect liver cells, while zedoaria, white flower herb and other drugs can directly inhibit tumor growth. The two drugs work together to improve the patient's physical condition and exert anti-tumor effects, which is consistent with the pathogenesis of liver cancer, namely "deficiency of vital energy and internal accumulation of evil toxins".

[0025] (2) Clear components and scientific ratios: The present invention determines the optimal mass fraction range of each component by screening, so that the effective ingredients of each medicinal material can work synergistically and the therapeutic effect is stable, thus overcoming the defects of vague components and arbitrary ratios in traditional empirical prescriptions.

[0026] (3) Multi-target effects: The various ingredients in the composition (such as ginsenosides, astragalus polysaccharides, curcumol, and Hedyotis diffusa extract) exert their effects through multiple targets, including inhibiting tumor cell proliferation, inducing apoptosis, inhibiting angiogenesis, and enhancing immune function, resulting in comprehensive anti-tumor effects. Furthermore, the composition uses natural Chinese medicine, and licorice can harmonize various drugs and reduce toxicity. Clinically, the composition has no significant gastrointestinal side effects, such as bone marrow suppression, and is well tolerated by patients.

[0027] (4) Wide range of applications: It can be used for patients with different stages of hepatocellular carcinoma, especially those in the middle and late stages, those with postoperative recurrence, and those who cannot tolerate chemotherapy and radiotherapy; and it has a variety of dosage forms, which are convenient for patients to choose according to their needs. The preparation method is simple and controllable: It adopts a water extraction process, which is easy to operate and low in cost. By controlling parameters such as extraction temperature, time, and concentration conditions, the product quality can be guaranteed to be stable, making it suitable for industrial production. DETAILED DESCRIPTION

[0028] Various exemplary embodiments of the present invention are now described in detail. This detailed description should not be considered as a limitation of the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention. It should be understood that the terms used in the present invention are only for describing specific embodiments and are not intended to limit the present invention.

[0029] In addition, for numerical ranges in the present invention, it is understood that each intervening value between the upper and lower limits of the range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated value or intervening value in the stated range is also included in the present invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.

[0030] Unless otherwise indicated, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein may also be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of any conflict with any incorporated document, the contents of this specification shall prevail.

[0031] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments described herein without departing from the scope or spirit of the invention. Other embodiments will be apparent to those skilled in the art from the description of the invention. The description and examples are intended to be exemplary only.

[0032] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0033] The present invention provides a traditional Chinese medicine composition for treating hepatocellular carcinoma, comprising the following components in parts by weight:

[0034] 8-12 parts of ginseng, 13-17 parts of astragalus, 8-12 parts of angelica, 8-12 parts of polygonatum, 8-12 parts of zedoaria, 18-22 parts of oldenlandia diffusa, 8-12 parts of trillium, 3-6 parts of liquorice, 10-15 parts of scutellaria barbata and 5-10 parts of ganoderma lucidum spore powder.

[0035] The components in parts by mass are preferably: 8-10 parts of ginseng, 13-15 parts of astragalus, 8-10 parts of angelica, 8-10 parts of polygonatum, 8-10 parts of zedoaria, 18-20 parts of oldenlandia diffusa, 8-10 parts of trillium, 3-5 parts of liquorice, 10-12 parts of scutellaria barbata and 5-7 parts of ganoderma lucidum spore powder.

[0036] The present invention adds various Chinese medicinal components to achieve synergistic effects and jointly exert therapeutic effects, specifically:

[0037] Ginseng: Sweet and slightly bitter, with a neutral nature, it enters the lung, spleen, and heart meridians. It has the benefits of tonifying vital energy, restoring the meridians, strengthening the spleen and lungs, promoting fluid production and nourishing blood, and calming the mind and improving intelligence. Ginsenosides (such as Rg3 and Rb1) in ginseng can inhibit the proliferation of liver cancer cells, induce apoptosis, and enhance immune function (increasing T cell and NK cell activity).

[0038] Astragalus: Sweet in flavor and slightly warm in nature, it enters the lung and spleen meridians. It has the effects of tonifying qi and raising yang, strengthening the exterior and stopping sweating, promoting diuresis and reducing swelling, promoting fluid production and nourishing blood, relieving stagnation and numbness, expelling toxins and draining pus, and healing sores and promoting tissue regeneration. Astragalus polysaccharide, its main active ingredient, can enhance immune function (promoting cytokine secretion), inhibit tumor angiogenesis, and protect liver cells and improve liver function.

[0039] Angelica sinensis: Sweet and pungent in flavor, warm in nature, it enters the liver, heart, and spleen meridians, benefiting from nourishing and activating blood circulation, regulating menstruation and relieving pain, and moistening the intestines and promoting bowel movements. The ferulic acid and angelica polysaccharides in angelica sinensis can inhibit the migration and invasion of liver cancer cells, while also improving blood circulation and alleviating blood stasis symptoms.

[0040] Polygonatum sibiricum: Sweet in flavor and neutral in nature, it enters the spleen, lung, and kidney meridians, tonifying qi and nourishing yin, strengthening the spleen, moistening the lungs, and benefiting the kidneys. Polygonatum sibiricum polysaccharides can enhance immune function, provide antioxidant benefits, inhibit tumor cell proliferation, and protect liver cells from damage.

[0041] Curcuma zedoaria: Pungent and bitter in flavor, warm in nature, it enters the liver and spleen meridians, promoting qi and blood circulation, dissipating stagnation and relieving pain. The curcumol and curcumone in zedoaria oil can induce apoptosis in liver cancer cells and inhibit tumor angiogenesis, exerting anti-tumor effects.

[0042] Hedyotis diffusa: Slightly bitter and sweet, it has a cold nature and enters the stomach, large intestine, and small intestine meridians. It has the effects of clearing heat and detoxifying, promoting dampness and relieving stranguria. Its oleanolic acid and ursolic acid can inhibit the proliferation of liver cancer cells and enhance immune function.

[0043] Trillium gracile: Sweet, slightly spicy, and cooling in nature, it enters the liver and spleen meridians, clearing away heat and toxins, resolving phlegm and dispersing stagnation. The colchicine derivatives in Trillium gracile can inhibit tumor cell mitosis and induce apoptosis, demonstrating a clear inhibitory effect on liver cancer.

[0044] Licorice: Sweet and neutral in nature, it enters the Heart, Lung, Spleen, and Stomach meridians. It tonifies the spleen and replenishes Qi, clears away heat and detoxifies, eliminates phlegm and relieves cough, relieves pain, and harmonizes various medicinal ingredients. Glycyrrhizic acid protects liver cells, reduces inflammation, and harmonizes the properties of various medicinal ingredients in prescriptions, reducing toxic side effects.

[0045] Scutellaria barbata: Spicy and bitter in flavor, with a cold nature, it enters the lung, liver, and kidney meridians, and has the effects of clearing heat and detoxifying, removing blood stasis, and promoting diuresis. Its flavonoids can inhibit the proliferation of liver cancer cells, induce apoptosis, and improve microcirculation.

[0046] Ganoderma lucidum spore powder: Made from the seeds of Ganoderma lucidum, it has the benefits of tonifying Qi, calming the mind, and relieving cough and asthma. The Ganoderma lucidum triterpenes and polysaccharides it contains can enhance immune function (increasing NK cell and T cell activity), inhibit tumor cell proliferation, and mitigate the side effects of chemotherapy and radiotherapy.

[0047] In the present invention, the traditional Chinese medicine composition further comprises: 10 to 15 parts of Artemisia capillaris.

[0048] In the present invention, the traditional Chinese medicine composition further comprises: 10 to 15 parts of Poria cocos and 5 to 8 parts of Alisma orientalis.

[0049] In actual application, if the patient has abnormal liver function (such as jaundice) or symptoms such as abdominal distension and ascites, Artemisia capillaris, Poria cocos and Alisma orientalis can be added.

[0050] The present invention also provides a method for preparing the traditional Chinese medicine composition for treating hepatocellular carcinoma described in the above technical solution, comprising the following steps:

[0051] Take each component medicinal material, remove impurities, wash and dry, and then grind to obtain 20-40 mesh medicinal material coarse powder;

[0052] Mixing the crude powder of the medicinal material with water, performing a first soaking, then performing a first stage of decoction, and filtering to obtain a first filtrate and a first filter residue;

[0053] adding water to the first filter residue, performing a second stage of decoction, and filtering to obtain a second filtrate and a second filter residue;

[0054] The first filtrate and the second filtrate are mixed and then concentrated to obtain a dry paste;

[0055] The dry paste is dried to obtain dry paste powder, which is the traditional Chinese medicine composition for treating hepatocellular carcinoma.

[0056] In the present invention, the mass ratio of the first soaked Chinese medicinal material coarse powder to water is 1:8-12, and the soaking time is 30-60 minutes.

[0057] In the present invention, the first stage of decoction is preferably: heating to boiling, and then continuing to decoct for 1.5 to 2.5 hours.

[0058] In the present invention, the mass ratio of the first filter residue to water in the second stage of decoction is preferably 1:6-8. The second stage of decoction is preferably: heating to boiling and then continuing to decoct for 1.0-1.5 hours.

[0059] In the present invention, the concentration is preferably as follows: placing the mixture of the first filtrate and the second filtrate in a vacuum concentrator, and concentrating it to a dry paste with a relative density of 1.10-1.20 at 60-70°C and a vacuum degree of 0.06-0.08MPa, wherein the relative density is measured at a temperature of 60°C.

[0060] In the present invention, the drying method is preferably spray drying or vacuum freeze drying; the dry paste powder is preferably prepared into decoction, tablets, capsules, granules or oral liquid.

[0061] The present invention does not impose any particular restrictions on the conditions of spray drying or vacuum freeze drying, and parameters well known to those skilled in the art that can achieve the desired drying effect may be employed. When the dry paste powder is formulated into a decoction, tablet, capsule, granule, or oral solution, auxiliary agents well known to those skilled in the art may be optionally added.

[0062] The present invention also provides the use of the traditional Chinese medicine composition for treating hepatocellular carcinoma described in the above technical solution in drugs for treating hepatocellular carcinoma.

[0063] Example 1 Basic formula of Chinese medicine composition (decoction)

[0064] (1) Weigh the following medicinal materials: 10 parts of ginseng, 15 parts of astragalus, 10 parts of angelica, 10 parts of polygonatum, 10 parts of zedoaria, 20 parts of oldenlandia diffusa, 10 parts of trifoliate vine, 5 parts of liquorice, 12 parts of scutellaria barbata, and 8 parts of ganoderma lucidum spore powder;

[0065] (2) Raw material pretreatment: Take the above medicinal materials, remove impurities, wash them, dry them at 65°C, and grind them into 30 mesh coarse powder;

[0066] (3) Extraction: Mix the coarse powder, add 10 times the weight of purified water, soak for 45 minutes, heat to boiling, then simmer for 2 hours, filter to obtain the first filtrate; add 7 times the weight of purified water to the residue, boil, then simmer for 1.2 hours, filter to obtain the second filtrate; combine the two filtrates to obtain a decoction.

[0067] Example 2 Chinese medicine composition (capsule) containing Artemisia capillaris

[0068] (1) Weigh the following medicinal materials: 8 parts of ginseng, 17 parts of astragalus, 8 parts of angelica, 12 parts of polygonatum, 8 parts of zedoaria, 22 parts of oldenlandia diffusa, 8 parts of trifoliate vine, 6 parts of liquorice, 10 parts of barbata, 10 parts of ganoderma lucidum spore powder, and 12 parts of capillaris;

[0069] (2) Raw material pretreatment: remove impurities from each medicinal material, wash it, dry it at 60°C, and grind it into 20-mesh coarse powder;

[0070] (3) Extraction: Mix the crude powder, add 12 times the weight of purified water, soak for 60 minutes, boil and simmer for 2.5 hours, filter to obtain the first filtrate; add 8 times the weight of purified water to the residue, boil and simmer for 1.5 hours, filter to obtain the second filtrate; combine the filtrates;

[0071] (4) Concentration: Concentrate to a dry paste with a relative density of 1.15 (60°C) at a temperature of 60°C and a vacuum of 0.07 MPa;

[0072] (5) Drying: Drying is performed by spray drying to obtain a dry paste powder, wherein the spray drying parameters are an inlet air temperature of 190°C and an outlet air temperature of 85°C;

[0073] (6) Formulation: Add 8 parts of microcrystalline cellulose to the dry paste powder, mix well, and fill into size 0 hollow capsules, each capsule containing 0.3 g of dry paste powder.

[0074] Example 3 Chinese medicine composition containing Poria cocos and Rhizoma Alismatis (tablets)

[0075] (1) Weigh the following medicinal materials: 12 parts of ginseng, 13 parts of astragalus, 12 parts of angelica, 8 parts of polygonatum, 12 parts of zedoaria, 18 parts of hedyotis diffusa, 12 parts of trillium, 3 parts of liquorice, 15 parts of barbata, 5 parts of ganoderma lucidum spore powder, 12 parts of tuckahoe, and 6 parts of oriental rhizome.

[0076] (2) Raw material pretreatment: remove impurities from each medicinal material, wash it, dry it at 70°C, and grind it into 40 mesh coarse powder;

[0077] (3) Extraction: Mix the crude powder, add 8 times the weight of purified water, soak for 30 minutes, boil and simmer for 1.5 hours, filter to obtain the first filtrate; add 6 times the weight of purified water to the residue, boil and simmer for 1 hour, filter to obtain the second filtrate; combine the filtrates;

[0078] (4) Concentration: Concentrate to a dry paste with a relative density of 1.20 (60°C) at a temperature of 70°C and a vacuum of 0.08 MPa;

[0079] (5) Drying: Drying is performed by vacuum freeze drying to obtain dry paste powder. The freeze drying conditions are: pre-freezing temperature -40°C, sublimation drying temperature -15°C, and desorption drying temperature 35°C;

[0080] (6) Formulation: Add 15 parts of lactose, 3 parts of sodium starch glycolate, and 1 part of magnesium stearate to the dry paste powder, mix well, and granulate. Dry at 60°C, shape the granules, and compress them into tablets (each tablet weighs 0.5 g).

[0081] Test Case

[0082] (1) Experimental materials

[0083] SPF Kunming mice (weight 20±2g), H22 liver cancer cell line, the Chinese medicine composition of Examples 1-3 (decoction, concentration of 0.5g crude drug / mL respectively), positive control drug sorafenib (concentration 0.2mg / mL).

[0084] (2) Model establishment

[0085] Take H22 cells in the logarithmic growth phase and adjust the concentration to 1×10 7 Each mouse was subcutaneously inoculated with 0.2 mL of the drug into the axilla of the right forelimb to establish an H22 liver cancer model.

[0086] (3) Grouping and drug administration

[0087] The model mice were randomly divided into 5 groups (n=10):

[0088] Model group: gavage with 0.2 mL of normal saline per rat per day;

[0089] Positive control group: oral administration of sorafenib 0.2 mL / animal / day;

[0090] Group 1: gavage with 0.2 mL of the decoction of Example 1 per animal per day;

[0091] Example 2 group: gavage of the decoction of Example 2 (equivalent to Example 1 in terms of crude drug amount) 0.2 mL / animal / day;

[0092] Group 3 of Example 3 was gavaged with the decoction of Example 3 (equivalent to that of Example 1 based on the crude drug amount) at 0.2 mL per animal per day.

[0093] The drug was administered starting on the second day after vaccination and continued for 14 days.

[0094] (4) Detection indicators

[0095] Tumor volume: The long diameter (a) and short diameter (b) of the tumor were measured every 3 days, and the formula V = ab 2 / 2 to calculate tumor volume;

[0096] Survival rate: observe and record the survival of mice and draw a survival rate curve;

[0097] Liver function indicators: After the administration, blood was collected from the eye sockets to test the serum ALT (alanine aminotransferase) and AST (aspartate aminotransferase) levels.

[0098] (5) Experimental results

[0099] Tumor volume: Compared with the model group, the tumor volumes of Examples 1-3 groups were significantly reduced (P < 0.05 or P < 0.01). Among them, the effects of Example 2 (containing Artemisia capillaris) and Example 3 (containing Poria cocos and Alisma orientalis) were better than those of Example 1 group and were comparable to those of the positive control group.

[0100] Survival rate: The survival rate of the model group mice was 30% at 21 days of observation, while the survival rates of the Example 1-3 groups were 60%, 70%, and 75%, respectively, and the survival rate of the positive control group was 65%, indicating that the composition of the present invention can significantly improve the survival rate of the model mice;

[0101] Liver function: The serum ALT and AST levels of the Example 1-3 groups were significantly lower than those of the model group (P<0.05), and lower than those of the positive control group, indicating that the composition has a protective effect on liver cells.

[0102] The results show that the Chinese medicine composition of the present invention can significantly inhibit the growth of liver cancer tumors, improve the survival rate and protect liver function, and has a good effect in treating hepatocellular carcinoma.

[0103] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and not to limit it. Although the present invention has been described in detail with reference to the above embodiments, ordinary technicians in the field should understand that the specific implementation methods of the present invention can still be modified or replaced by equivalents. Any modification or equivalent replacement that does not depart from the spirit and scope of the present invention should be covered by the scope of protection of the claims of the present invention.

Claims

1. A Chinese medicine composition for treating hepatocellular carcinoma, characterized in that: The composition includes the following parts by weight: 8-12 parts of ginseng, 13-17 parts of astragalus, 8-12 parts of angelica, 8-12 parts of polygonatum, 8-12 parts of zedoaria, 18-22 parts of oldenlandia diffusa, 8-12 parts of trillium, 3-6 parts of liquorice, 10-15 parts of scutellaria barbata and 5-10 parts of ganoderma lucidum spore powder.

2. The Chinese medicine composition for treating hepatocellular carcinoma according to claim 1, characterized in that The traditional Chinese medicine composition further comprises 10 to 15 portions of Artemisia capillaris.

3. The Chinese medicine composition for treating hepatocellular carcinoma according to claim 1, characterized in that The traditional Chinese medicine composition further comprises: 10-15 parts of Poria cocos and 5-8 parts of Alisma orientalis.

4. A method for preparing the traditional Chinese medicine composition for treating hepatocellular carcinoma according to any one of claims 1 to 3, characterized in that: The following steps are involved: Take each component medicinal material, remove impurities, wash and dry, and then grind to obtain 20-40 mesh medicinal material coarse powder; Mixing the crude medicinal material powder with water, performing a first soaking, then performing a first stage of decoction, and filtering to obtain a first filtrate and a first filter residue; adding water to the first filter residue, performing a second stage of decoction, and filtering to obtain a second filtrate and a second filter residue; The first filtrate and the second filtrate are mixed and then concentrated to obtain a dry paste; The dry paste is dried to obtain dry paste powder, which is the traditional Chinese medicine composition for treating hepatocellular carcinoma.

5. The method for preparing the Chinese medicine composition for treating hepatocellular carcinoma according to claim 4, wherein: The mass ratio of the first soaking Chinese medicinal material coarse powder to water is 1:8-12, and the soaking time is 30-60 minutes.

6. The method for preparing the Chinese medicine composition for treating hepatocellular carcinoma according to claim 4, wherein: The first stage of decoction is specifically: heating to boiling and then continuing to decoct for 1.5 to 2.5 hours.

7. The method for preparing the Chinese medicine composition for treating hepatocellular carcinoma according to claim 4, wherein: The mass ratio of the first filter residue to water in the second stage of decoction is 1:6-8. The second stage of decoction is specifically: heating to boiling and then continuing to decoct for 1.0-1.5 hours.

8. The method for preparing the Chinese medicine composition for treating hepatocellular carcinoma according to claim 4, wherein: The concentration is specifically as follows: placing the mixture of the first filtrate and the second filtrate in a vacuum concentrator, and concentrating it to a dry paste with a relative density of 1.10-1.20 at 60-70°C and a vacuum degree of 0.06-0.08MPa, wherein the relative density is measured at a temperature of 60°C.

9. The method for preparing the Chinese medicine composition for treating hepatocellular carcinoma according to claim 4, wherein: The drying method is spray drying or vacuum freeze drying; the obtained dry paste powder can be made into decoction, tablets, capsules, granules or oral liquid.

10. Use of the traditional Chinese medicine composition for treating hepatocellular carcinoma according to any one of claims 1 to 3 in a medicine for treating hepatocellular carcinoma.